Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Androsta-3,5-diene-7,17-dione** (brand name: Arimistane) is a steroidal small molecule that functions as a **suicide (irreversible) aromatase inhibitor**. It is a naturally occurring metabolite of 7-Keto DHEA and does not itself convert into testosterone or estrogen. By irreversibly binding to and inactivating the aromatase enzyme (CYP19A1), it blocks the conversion of androgens (e.g., testosterone) into estrogens, thereby reducing circulating estrogen levels and secondarily elevating endogenous testosterone. It is primarily marketed as a dietary supplement by Hi-Tech Pharmaceuticals, which holds the trademark for the brand name 'Arimistane,' and is widely used in bodybuilding for post-cycle therapy (PCT) following prohormone or anabolic steroid cycles. Claimed benefits include reducing estrogen and cortisol levels, increasing testosterone, and preventing gynecomastia. The compound is banned by the World Anti-Doping Agency (WADA) and has been classified by the FDA as a prescription drug ingredient that should not be included in dietary supplements, though it continues to be sold over-the-counter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on androsta-3,5-diene-7,17-dione.